Lonaprofen

Lonaprofen

SCHEMBL2109183

COC(=O)C(C)Oc1ccc2ccccc2c1Cl

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCEH1 Q6PIU2 8/20 0.56
LMNA P02545 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.46
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
HPGD P15428 1/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
F9 P00740 1/20 0.43
PLAU P00749 1/20 0.43
CYP2A6 P11509 1/20 0.42
MAPT P10636 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lonaprofen SCHEMBL29670159 1.00 NCEH1 (0.56) NCEH1LMNASMN1; SMN2NPC1TP53
SCHEMBL11810433 0.86 LMNA (0.53) NCEH1LMNASMN1; SMN2NPC1TP53
SCHEMBL11807492 0.84 LMNA (0.55) NCEH1LMNASMN1; SMN2NPC1TP53
SCHEMBL11807725 0.84 NCEH1 (0.54) NCEH1LMNASMN1; SMN2NPC1TP53
SCHEMBL11798018 0.84 LMNA (0.51) NCEH1LMNASMN1; SMN2NPC1TP53
SCHEMBL11804487 0.83 LMNA (0.47) NCEH1LMNASMN1; SMN2NPC1TP53
SCHEMBL11800432 0.82 LMNA (0.49) NCEH1LMNASMN1; SMN2NPC1TP53
SCHEMBL23368144 0.79 TSHR (0.54) LMNASMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL18331090 0.79 TSHR (0.54) LMNASMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL13390983 0.78 MAPT (0.58) NCEH1LMNASMN1; SMN2NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
CN-101011374-A Non-steroidal analgesic-antipyretic medicament paracetamol containing carboxyl group CHEN WENZHAN (CN) 2007-08-08 CN claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
CN-1969835-A Carboxyl contained NSAIDS (nonsteroidal anti-inflammatory drugs) salt CHEN WENZHAN (CN) 2007-05-30 CN claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-3968145-A ANALGESIC, ANTIPYRETIC, ANTIPHLOGISTIC A. MENARINI S.A.S. (IT) 1976-07-06 US claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 US disclosed
US-20050002865-A1 Diagnostic/therapeutic agents AMERSHAM HEALTH AS (NO) 2005-01-06 US disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP disclosed
US-3968145-A ANALGESIC, ANTIPYRETIC, ANTIPHLOGISTIC A. MENARINI S.A.S. (IT) 1976-07-06 US disclosed
US-3968145-A ANALGESIC, ANTIPYRETIC, ANTIPHLOGISTIC A. MENARINI S.A.S. (IT) 1976-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 NCEH1 2703/4885LMNA 1461/4885SMN1; SMN2 1551/4885
US-20050002865-A1 Diagnostic/therapeutic agents FUS, HNRNPF, HNRNPR NCEH1 3936/4885LMNA 1180/4885SMN1; SMN2 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.